Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 April 2022 | Story Elsabé Brits
Andre Roodt and Alice Brink
Prof Andreas Roodt and Prof Alice Brink are two of the inventors of the ‘Multinuclear complexes and their preparation patent.

According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six. The most common cancers are breast, lung, colon, rectum, and prostate cancers. There is a constant need to provide methods to diagnose and treat cancer-related tumours.  Current research strategies focus on eliminating cancer cells with the minimum damage to surrounding healthy cells.

A limitation of current technologies is that they are mostly based on the separate identification of cancer (diagnostic), followed by treatment (therapy) using chemotherapy and/or radiotherapy. To fit both needs at the same time and with similar or identical compounds, the principle of theranostic medicine was identified. This concept employs both diagnosing (by imaging) cancer and delivering therapy (treatment) simultaneously, which has been receiving increased attention internationally.

Collaborating with the University of Zurich
A University of the Free State (UFS) team, together with a team from the University of Zürich, conducted exciting research in this area and filed a patent titled ‘Multinuclear complexes and their preparation’. The patent was granted in South Africa and by the European Patent Office. It is being validated in selected European countries. The patent is pending in the USA, Japan, Hong Kong, and India. The inventors from the UFS are Prof Andreas Roodt, Prof Alice Brink, Dr Pennie Mokolokolo, and Dr Vincent Dumisani Kama. The approach that their technology takes is to enable the synthesis of a multinuclear compound/s, which may contain different pre-selected radioisotopes, to allow both imaging and therapy to the cancer site(s) with one and the same metal-organic complex.

So far, high-yield production of compounds has been successfully innovated, which contain both an imaging (in particular the widely utilised imaging isotope Technetium-99m) and therapeutic (typically the therapeutic isotope Rhenium-186) radioactive isotope(s), optionally carrying an additional cytotoxic agent. (Chemotherapy uses anti-cancer [cytotoxic] drugs to destroy cancer cells.)

Nuclear medicine technologies
In the next phase of the research, a lead compound portfolio of four to five model pharmaceuticals containing these metal nuclides with appropriate directing groups to target cancer sites will be designed and constructed. A number of these entities are known and can be introduced through different techniques. These will then undergo full characterisation and efficacy evaluation in biological models (in vitro), followed by extensive animal and human trials.

The technology will be delivered as a product or service in the way that current nuclear medicine technologies are delivered.

The fact that this product(s) contains both imaging and therapeutic radionuclides or cytotoxic modalities, enables detailed tracking of the pharmaceutical and monitoring of the tumours' response to the therapy. Not directly related to the patent, but an asset to it, is the fact that the incorporation of rhenium with a high atomic number (Z = 75) opens the additional opportunity to utilise the multinuclear compounds also as radiosensitisers. Synergistic effects, enhancing the therapeutic efficacy, can thus be expected in combination with radiotherapy.

The UFS would like to partner with a pharmaceutical company working in the field of nuclear medicine to commercialise this technology. Interested parties can contact Ravini Moodley at MoodleyR5@ufs.ac.za

News Archive

UFS awarded five South African Research Chairs
2016-09-30

Description: South African Research Chairs Tags: South African Research Chairs

From left to right, Prof Maryke Labuschagne,
Prof Corli Witthuhn (Vice-Rector: Research),
Prof Hendrik Swart and Prof Felicity Burt.

The UFS was awarded five SARChI (South African Research Chairs Initiative) research chairs, the main goal of which is to promote research excellence. In addition, there has been an increase in the rating of the University’s researchers as the result of raised academic standards over the past few years, in line with the UFS’s Academic Project. As of 2016 the UFS has 127 NRF-rated researchers.

The following research chairs have been awarded to the UFS since 2013:

Prof Hendrik Swart from the Department of Physics is the research chair of Solid State Luminescent and Advanced Materials (2013-2017). Prof Swart’s research may assist in reducing vulnerability and contributing to poverty alleviation by providing affordable lighting for people in rural areas through fabricating phosphors and the development of nanophosphors.

Prof Maryke Labuschagne from the Department of Plant Sciences is the research chair of Disease Resistance and Quality in Field Crops (2016-2020). Prof Labuschagne believes that food security is one of the key factors for stability and prosperity on the continent. Her research and that of her students focuses on the genetic improvement of food security crops in Africa, including such staples as maize and cassava.

Research Chairs have been designed, to attract
and retain excellence in research and innovation
at South African universities.

Prof Melanie Walker, from the Department of Higher Education and Human Development, was awarded the research chair from 2013 to 2017. Prof Walker’s research interrogates the role of higher education in order to advance human development and justice in education and society, especially in relation to severe inequalities and poverty. Significantly, it asks what kind of societies we want, what is important in a democratic society, and thus, what kind of higher education is valuable, relevant and desirable.

Prof Felicity Burt from the Department of Medical Microbiology was recently awarded the research chair from 2016 to 2020, to investigate medically significant vector-borne and zoonotic viruses currently; to define associations between these viruses and specific disease manifestations that have previously not been described in our region, to increase awareness of these pathogens; to further our understanding of host immune responses, which should facilitate development of novel treatments or vaccines and drug discovery.

The Humanities without Borders: Trauma, History and Memory research chair was awarded from 2016 to 2020. The Institute for Social Justice and Reconciliation will use this research chair to investigate historical trauma within two African contexts – those of South Africa and Rwanda. The research hopes to bring insight into the role that memory plays in the formation of the experience of trauma, and to bring about healing of the trauma.

Research Chairs have been designed by the Department of Science and Technology, together with the National Research Foundation, to attract and retain excellence in research and innovation at South African public universities.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept